Drug Trial Radar · NCT01728467
The Effects of RVX000222 on Glucose Metabolism in Individuals With Pre-diabetes
Last checked: Nov 19, 2026Latest source record: Apr 2, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Nov 2012
Primary completion
Mar 2014
Study completion Mar 2014
Sponsor
- Lead sponsor
- Resverlogix CorpIndustry
- Sponsor type
- Industry
- Collaborators
- Baker Heart and Diabetes Institute; Nucleus Network Ltd
- First posted
- Nov 19, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study builds on data that high-density lipoprotein (HDL) has a number of potentially beneficial effects including directly modulating glucose metabolism through multiple mechanisms. The primary objective of this study is to determine the effects of RVX000222 on postprandial plasma glucose in male individuals with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), during a frequently sampled oral glucose tolerance test (OGTT).
Conditions
- Diabetes
Interventions
RVX000222Drug
capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
Placebo, RVX000222Drug
capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in plasma glucose following treatment with RVX000222 compared to placeboTime frame: 29-33 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Baker IDI Heart and Diabetes Institute 75 Commercial Road,
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.